Increasing prevalence of
chronic diseases such as diabetes, cancer, and osteoporosis and favorable
government policies for the pharmaceutical sector are expected to drive the
growth of this market.
The Indian
Heparin market is
expected to reach USD 883.0 Million in 2022 from USD 381.8 Million in 2016 and
is expected to register a CAGR of 15.0%.
+ Market Dynamics
+ Drivers
+ Growing Incidence of
Coagulation Disorders
+ Government Support for the Pharmaceutical Industry
Download PDF Brochure @
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=77044734
The Indian peptide drugs market is classified into hormonal, antifungal, antibiotic, ACE inhibitor and others. The hormonal segment is expected to dominate the Indian peptide drugs market in 2016. Growing incidence and prevalence rate of diabetes in India and rising ageing population are the major driving factors for this segment.
The Indian peptide drugs
market is segmented into diabetes, infectious disease, cancer, cardiology,
osteoporosis, gynecological application, and other applications. In 2016, the
diabetes segment is expected to account for the largest share of the Indian
peptide drugs market, by application. The growth in the segment can be
primarily attributed to increasing incidence and prevalence of diabetes cases
in the country.
View complete press release:-
https://www.marketsandmarkets.com/PressReleases/indian-peptides-heparin.asp